-
1 Comment
Rozdil Capital Corporation is currently in a long term downtrend where the price is trading 0.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 0.0.
Rozdil Capital Corporation's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 110.0% to $-17K since the same quarter in the previous year.
Finally, its free cash flow fell by 18.3% to $-6K since the same quarter in the previous year.
Based on the above factors, Rozdil Capital Corporation gets an overall score of 1/5.
| Exchange | V |
|---|---|
| CurrencyCode | CAD |
| ISIN | None |
| Sector | Financial Services |
| Industry | Shell Companies |
| Market Cap | 1M |
|---|---|
| PE Ratio | None |
| Dividend Yield | 0.0% |
| Beta | 1.01 |
| Target Price | None |
Thiogenesis Therapeutics, Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of a range of unmet genetic and central nervous system diseases. Its lead product candidate under development is TTI-0102, a prodrug consisting of cysteamine and pantetheine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke. The company is headquartered in Toronto, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ROZ-P.V using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
